Loading...

Zhejiang Taimei Medical Technology Co., Ltd.

2576.HKHKSE
Technology
Software - Application
HK$3.40
HK$-0.02(-0.58%)

Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) Stock Overview

Explore Zhejiang Taimei Medical Technology Co., Ltd.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap2B
P/E Ratio-8.34
EPS (TTM)$-0.43
ROE-0.21%
Fundamental Analysis

AI Price Forecasts

1 Week$3.29
1 Month$2.20
3 Months$2.31
1 Year Target$1.55

2576.HK Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Zhejiang Taimei Medical Technology Co., Ltd. (2576.HK) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 49.65, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.55.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.34 and a market capitalization of 2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

49.65RSI (14)
0.00MACD
33.05ADX
Stats data is not available for 2576.HKStats details for 2576.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for 2576.HKAnalyst Recommendations details for 2576.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Zhejiang Taimei Medical Technology Co., Ltd. provides digital operation platform for the biopharma industry in China. The company offers TrialOS, a drug digital cooperation platform that connects the cycle of hospitals, pharmaceutical companies, third-party providers, regulatory authorities, patients, and other industry stakeholders. It offers software solutions, such as eCooperate, a clinical trial cooperation platform that optimizes clinical research operations management systems, as well as support decision-making with big data technology; eArchives, a clinical trial master file system; eCollect, an electronic data capture system; eCollege, a training management system; eQuality, an electronic quality audit system; eBalance, an interactive Web-based response system; eVisit Patient Reported Outcomes, a solution that enhances the ability of patients to enter data and the accuracy of clinical trial data; eTime, a project man-hour management system; and eImage, a medical image reading system. It also provides hospital software, including eTrial, a phase I ward management system; eSite, a clinical trial management system for GCP sites; GCP-X, an intelligent clinical trial platform; NomenCTMS, a clinical research project management system for GCP sites; eScreening, a subject information management and duplicate checking system; Intelligent Investigator, an initiated clinical trial platform; IIT-EDC, a clinical research data management platform; and Investigator-Initiated Clinical Trial Management System, a project management system. In addition, the company offers pharmacovigilance software solutions, such as eSafety global pharmacovigilance system; eSafety, an intelligent professional information system for pharmacovigilance; and SAE Manager, a safety data communication and management system for clinical trials. Further, it provides marketing software and digital innovation solutions. The company was founded in 2013 and is headquartered in Jiaxing, China.

CEO

Zhao Lu

Employees

627

Headquarters

No.9 Building, Jiaxing

Founded

1970

Frequently Asked Questions

;